The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Methodology
- PMID: 36595113
- DOI: 10.1245/s10434-022-12990-3
The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Methodology
Abstract
Background: A group of experts from the Peritoneal Surface Oncology Group International (PSOGI) and the BIG-RENAPE group carried out a consensus among surgeons experienced in treating peritoneal malignancies from around the world to derive recommendations on indications of hyperthermic intraperitoneal chemotherapy (HIPEC), choice and details of HIPEC regimens, and areas for future research. This manuscript describes the methodology of achieving this consensus and the degree of participation of experts.
Methods: The Delphi technique was used and the questionnaire comprised three categories: evidence-based recommendations using the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) system with the PICO (patient, intervention, comparison, and outcome) method, an opinion survey, and research recommendations. A consensus was achieved if any one option had >50% of votes, or positive or negative recommendations combined had > 70% of votes.
Results: Of the 145 experts solicited, 71.1% in round I and 72.2% in round II took the survey. Participation was highest among surgeons treating both gastrointestinal and gynecological malignancies. Of 113 questions, after round I, a consensus was achieved for 72 (63.7%) questions, and after the second round, consensus was achieved for another 22 (19.4%) questions, making a total of 94 (83.1%) questions for which a consensus was achieved.
Conclusion: This consensus was carried out using a thorough review of literature and robust rating of evidence, and included key experts and opinion leaders from across the world. The results could guide clinicians on the use of HIPEC, both in their day-to-day clinical practice and in designing clinical trials.
© 2023. Society of Surgical Oncology.
Comment in
-
ASO Author Reflections: International Standardization of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocols-Malignant Peritoneal Mesothelioma as a Model.Ann Surg Oncol. 2023 Nov;30(12):7858-7859. doi: 10.1245/s10434-023-14120-z. Epub 2023 Aug 25. Ann Surg Oncol. 2023. PMID: 37626249 No abstract available.
References
-
- Witmer H, Turaga K. Current indications for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastrointestinal malignancies. Adv Oncol. 2021;1:49–61. https://doi.org/10.1016/j.yao.2021.02.005 . - DOI
-
- Valle M, Van der Speeten K, Garofalo A. Laparoscopic hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) in the management of refractory malignant ascites: a multi-institutional retrospective analysis in 52 patients. J Surg Oncol. 2009;100:331–4. https://doi.org/10.1002/jso.21321 . - DOI - PubMed
-
- White MG, Badgwell BD. Laparoscopic heated intraperitoneal chemotherapy in the treatment of carcinomatosis of gastric adenocarcinoma origin. J Clin Med. 2021;10(20):4757. https://doi.org/10.3390/jcm10204757 . - DOI - PubMed - PMC
-
- Zhang C, Patel A, Hegeholz D, et al. Cytoreductive surgery with HIPEC is a safe and effective palliative option in chemo refractory symptomatic peritoneal metastasis. Ann Surg Oncol. 2022;29:3337–46. https://doi.org/10.1245/s10434-022-11323-8 . - DOI - PubMed
-
- Bhatt A, Glehen O. Extent of peritoneal resection for peritoneal metastases: looking beyond a complete cytoreduction. Ann Surg Oncol. 2020;27(5):1458–70. https://doi.org/10.1245/s10434-020-08208-z . - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
